Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy and Ozempic drugs lag, which could prompt the Danish drugmaker to cut its ...

Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as investor worries intensify that the obesity drug market pioneer has lost its ...

European pharma companies warned the European Commission president at a meeting on Tuesday that US tariffs wou ...

Indian markets ended lower, snapping a seven-day winning streak as investors booked profits ahead of U.S. tariff announcements. Sensex fell 729 points, Nifty declined 182 points, with most sectors in ...

Denmark’s economy was reshaped by Novo Nordisk and obesity drugs. That identity is now under attack on multiple fronts, from ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

Novo Nordisk A/S Bagsværd, Denmark, 3 April 2025 – Novo Nordisk today announced the following changes in Executive Management. After a distinguished career of 28 years with Novo Nordisk, hereof ...

In the sleepy suburb of Bagsværd, a 25-minute train ride from Denmark’s capital of Copenhagen, weight-loss drugmaker Novo Nordisk is everywhere. Street after street is filled with the company ...

LONDON/COPENHAGEN (Reuters) - Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the Danish drugmaker said on Thursday.